1191997-63-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-methyl 2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoate is used as a reagent for the synthesis of various drugs. Its unique structure and chiral center contribute to its potential as a key component in the development of new medications.
Used in Organic Chemistry:
In the field of organic chemistry, (S)-methyl 2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoate serves as a valuable reagent for conducting various chemical reactions and syntheses. Its properties and reactivity make it a useful tool for researchers in this domain.
While the compound may possess potential biological activities, further research is necessary to fully understand its properties and explore additional applications in different industries.

Upstream product

• 1191997-59-7 ethyl (2E)-3-(2-chlorophenoxy)but-2-enoate 
• 95-57-8 2-monochlorophenol 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 1191997-60-0 (E)-4-bromo-3-(2-chloro-phenoxy)-but-2-enoic acid ethyl ester 

Downstream Products

• 1191997-64-4 (S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid 

Relevant academic research and scientific papers

Deuterated pyrrolidone derivative Pharmaceutical compositions and uses thereof

The invention relates to a deuterated pyrrolidone derivative and a preparation method thereof, and also relates to application of the deuterated pyrrolidone derivative and a pharmaceutical composition thereof in treatment and prevention of metabolic disorder related diseases, and belongs to the field of medicines.

Pyrrolidinone derivative as glucokinase activator and preparation method and application thereof

The invention provides a pyrrolidone derivative, and more specifically relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method and application thereof. These compounds and contain their pharmaceutical compositions useful as glucokinase activators for the treatment of metabolic diseases and disorders. R1 . R2 , R3 , R4 , R5 , X And A are as described in the present invention.

PYRROLIDINONE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.